

11.1 Supplemental Antioxidant Nutrients: Combined Vitamins and Trace Elements

August 2015

2015 Recommendation: *Based on 8 level 1 and 19 level 2 studies, we do not recommend the use of supplemental combined vitamins and trace elements in critically ill patients.*

2015 Discussion: The committee noted that with the addition of 3 new trials (Nogueira 2013, Bloos in submission, Woth 2014), there were no significant treatment effects, only a trend towards reduction in mortality, infections, and duration of mechanical ventilation. The committee noted that enterally administered supplemental antioxidants seemed to exert the most positive effect on mortality; however the committee felt that a clinical recommendation on this subgroup result alone was not warranted as the results were driven by largely one study (Crimi). Concern was expressed about the differences in the types of antioxidant nutrients used in the studies and the heterogeneity of the trials but the high generalizability of the results from many large, multicentre trials was also noted. There were also concerns raised about the safety of these micronutrients (REDOXS and METAPLUS studies) particularly in the setting of renal failure. Because of the lack of significant treatment effect and emerging safety concerns, the committee downgraded their recommendation and recommended against the routine use of supplemental antioxidants in critically ill patients.

2013 Recommendation: *Based on 7 level 1 and 17 level 2 studies, the use of supplemental combined vitamins and trace elements should be considered in critically ill patients.*

2013 Discussion: The committee noted that with the addition of 8 new trials (Lindner 2004, El Attar 2009, González 2009, Andrews 2011, Manzanares 2011, Valenta 2011, Schneider 2011 and Heyland 2013), there was a moderate treatment effect but narrow confidence intervals with respect to a reduction in mortality, infections and a trend towards a reduction in mechanical ventilation similar to a recent systematic review (1). The committee noted that the large REDOXS trial was negative but that the signal of benefit persisted despite its inclusion in the meta-analysis. They considered that the dose of antioxidants in the REDOXS trial may have been insufficient and there is still uncertainty about the optimal composition and dose of supplemental vitamins and trace elements. Concern was expressed about the differences in the types of antioxidant nutrients used in the studies and the heterogeneity of the trials but the high generalizability of the results from many large, multicentre trials was also noted. There were no concerns about the safety, feasibility and cost of these nutrients. The committee therefore agreed to continue with a recommendation that supplemental combined vitamins and trace elements should be considered.

(1) Manzanares W, Dhaliwal R, Jiang X, Murch L, Heyland DK. Antioxidant micronutrients in the critically ill: a systematic review and meta-analysis. Crit Care. 2012 Dec 12;16(2):R66

Semi Quantitative Scoring

Value	Definition	2009 Score (0,1,2,3)	2013 Score (0,1,2,3)	2015 Score (0,1,2,3)
Effect size	Magnitude of the absolute risk reduction attributable to the intervention listed--a higher score indicates a larger effect size	2	1 (mortality) 1 (infections)	1 (mortality) 0 (infections)
Confidence interval	95% confidence interval around the point estimate of the absolute risk reduction, or the pooled estimate (if more than one trial)--a higher score indicates a smaller confidence interval	3 (mortality) 2 (infections)	3 (mortality) 3 (infections)	2 (mortality) 2 (infections)
Validity	Refers to internal validity of the study (or studies) as measured by the presence of concealed randomization, blinded outcome adjudication, an intention to treat analysis, and an explicit definition of outcomes--a higher score indicates presence of more of these features in the trials appraised	2	3	2
Homogeneity or Reproducibility	Similar direction of findings among trials--a higher score indicates greater similarity of direction of findings among trials	2	1	2
Adequacy of control group	Extent to which the control group represented standard of care (large dissimilarities = 1, minor dissimilarities=2, usual care=3)	3	3	3
Biological plausibility	Consistent with understanding of mechanistic and previous clinical work (large inconsistencies =1, minimal inconsistencies =2, very consistent =3)	2	2	2
Generalizability	Likelihood of trial findings being replicated in other settings (low likelihood i.e. single centre =1, moderate likelihood i.e. multicentre with limited patient population or practice setting =2, high likelihood i.e. multicentre, heterogenous patients, diverse practice settings =3.	2	3	3
Low cost	Estimated cost of implementing the intervention listed--a higher score indicates a lower cost to implement the intervention in an average ICU	2	2	2
Feasible	Ease of implementing the intervention listed--a higher score indicates greater ease of implementing the intervention in an average ICU	2	2	2
Safety	Estimated probability of avoiding any significant harm that may be associated with the intervention listed--a higher score indicates a lower probability of harm	2	2	1

11.1 Supplemental Antioxidant Nutrients: Combined Vitamins and Trace Elements

Question: Does the addition of Supplemental Combined Vitamins and Trace Elements result in improved outcomes in the critically ill patient?

Summary of evidence: Of the 27 studies included, there were eight level 1 and nineteen level 2 studies reviewed that compared various antioxidants either as single nutrients (zinc, selenium) or as a combination of nutrients (selenium, copper, zinc, vit. A, C & E, N-acetylcysteine) given by various routes (IV/parenteral, enteral, combined parenteral and enteral). One study was published in 2 parts (Berger et al, Intensive Care Medicine 2001;27:91-100 and Berger et al, Nutrition Research;21:41-54) and the data listed here represent the data from the latter study (intent to treat). This study had two intervention arms i.e. selenium alone and selenium combined with zinc and α tocopherol compared to placebo and the data are presented in the meta-analysis as Berger 2001a and Berger 2001b respectively.

Mortality: Twenty-five studies reported on mortality and when the results were aggregated, antioxidant supplementation was associated with a trend towards a reduction in overall mortality (RR 0.89, 95% CI 0.79, 1.01, $p=0.06$, heterogeneity $I^2=25\%$; figure 1). Linder (2004) and Nogueira (2013) were excluded from the meta-analyses because the type of mortality was not specified but appeared to be 90 days and mortality was only reported as a percent of total deaths, respectively. When the 17 studies which delivered antioxidants via parental nutrition were sub-grouped and analysed, antioxidant supplementation was not associated with a reduction in overall mortality (RR 0.93, 95% CI 0.83, 1.05, $p=0.25$, heterogeneity $I^2=0\%$; figure 1). When the 4 studies which delivered antioxidants via enteral nutrition were sub-grouped and analysed, antioxidant supplementation was associated with a significant reduction in overall mortality (RR 0.68, 95% CI 0.54, 0.85, $p=0.0008$, heterogeneity $I^2=0\%$; figure 1). When the data from the subgroup comprised of the 3 studies which delivered antioxidants via both enteral and parental nutrition were aggregated, antioxidant supplementation had no effect on overall mortality (RR 1.07, 95% CI 0.92, 1.25, $p=0.38$, heterogeneity $I^2=0\%$; figure 1). The test for subgroup differences was significant ($p=0.005$).

Mortality (higher vs. lower mortality in control group): Subgroup analysis showed that antioxidant supplementation was associated with a significant reduction in overall mortality among patients with higher risk of death ($>10\%$ mortality in the control group) (RR 0.86, 95% CI 0.75, 1.00, $p=0.04$, heterogeneity $I^2=42\%$; figure 2). There was no significant effect observed for trials of patients with a lower mortality in the control group (RR 1.14, 95% CI 0.71, 1.81, $p=0.59$, heterogeneity $I^2=0\%$; figure 2). The test for subgroup differences was not significant ($p=0.27$).

Infections: When the 13 studies that reported on the number of patients with infectious complications were aggregated, antioxidant supplementation was associated with a trend towards reduction in overall infections (RR 0.95, 95% CI 0.88, 1.02, $p=0.14$, heterogeneity $I^2=0\%$; figure 3). When a subgroup analysis based on 7 studies which delivered antioxidants via parental nutrition was done, antioxidant supplementation was not associated with a reduction in infectious complications (RR 0.96, 95% CI 0.88, 1.05, $p=0.35$, heterogeneity $I^2=0\%$; figure 3). When a subgroup analysis based on 3 studies which delivered antioxidants via enteral nutrition was done, antioxidant supplementation had no effect on infectious complications (RR

1.10, 95% CI 0.60, 2.04, $p=0.75$, heterogeneity $I^2=38\%$; figure 3). When a third subgroup analysis based on 3 studies which delivered antioxidants via both enteral and parental nutrition was done, antioxidant supplementation was associated with a trend towards a reduction in infectious complications (RR 0.90, 95% CI 0.77, 1.05, $p=0.19$, heterogeneity $I^2=0\%$; figure 3). The test for subgroup differences was not significant ($p=0.70$).

Infections (higher vs. lower mortality in control group): Subgroup analysis showed that antioxidant supplementation was associated with a trend in a reduction in infectious complications among patients with higher risk of death (>10% mortality in the control group) (RR 0.95, 95% CI 0.88, 1.03, $p=0.20$, heterogeneity $I^2=0\%$; figure 4). There was no significant effect observed for patients in trials with a lower mortality in the control group (RR 0.87, 95% CI 0.69, 1.10, $p=0.25$, heterogeneity $I^2=0\%$; figure 4). The Maderazo study was not included in the analysis since it does not report on mortality. The test for subgroup differences was not significant ($p=0.33$).

ICU length of stay: When the 10 studies that reported ICU length of stay as a mean \pm standard deviation were aggregated, antioxidant supplementation had no effect on ICU length of stay (WMD 0.53, 95% CI -0.55, 1.61, $p=0.33$, heterogeneity $I^2=0\%$; figure 5). The result was the same for each of the 3 subgroups: six studies which delivered antioxidants via parental nutrition (WMD 0.08, 95% CI -2.47, 2.62, $p=0.95$, heterogeneity $I^2=20\%$; figure 5), one study which delivered antioxidants via enteral nutrition (WMD 3.30, 95% CI -8.55, 15.15, $p=0.59$; figure 5), and three studies which delivered antioxidants via both enteral and parental nutrition (WMD 0.35, 95% CI -0.97, 1.67, $p=0.60$, heterogeneity $I^2=0\%$; figure 5). The test for subgroup differences was not significant ($p=0.87$).

Hospital length of stay: When the 7 studies that reported hospital length of stay as a mean \pm standard deviation were aggregated, antioxidant supplementation had no effect on hospital length of stay (WMD -0.44, 95% CI -3.77, 2.89, $p=0.80$, heterogeneity $I^2=0\%$; figure 6). The result was the same for 2 of the subgroups: two studies which delivered antioxidants via parental nutrition (WMD -6.03, 95% CI -25.61, 13.55, $p=0.55$, heterogeneity $I^2=0\%$; figure 6), and one study which delivered antioxidants via enteral nutrition (WMD 2.34, 95% CI -5.05, 9.74, $p=0.53$; figure 6). However, in the subgroup of 3 studies in which antioxidants were delivered via both enteral and parental nutrition, antioxidant supplementation was associated with a trend towards a reduction in hospital length of stay (WMD -1.408, 95% CI -6.89, 4.09, $p=0.62$, heterogeneity $I^2=38\%$; figure 6). The test for subgroup differences was not significant ($p=0.61$).

Duration of mechanical ventilation: When the 8 studies that reported duration of ventilation as a mean \pm standard deviation were aggregated, antioxidant supplementation was associated with a trend towards a reduction in duration of ventilation (WMD -1.76, 95% CI -3.87, 0.36, $p=0.10$, heterogeneity $I^2=74\%$; figure 7). Subgroup analysis showed that antioxidant supplementation had no effect on duration of ventilation in the subgroup of 5 studies in which antioxidants were delivered via parental nutrition (WMD -2.22, 95% CI -6.07, 1.62, $p=0.26$, heterogeneity $I^2=78\%$; figure 7), nor in the subgroup consisting of 1 study in which antioxidants were delivered via both enteral and parental nutrition (WMD 0.40, 95% CI -1.91, 2.71, $p=0.73$; figure 7). However, in the subgroup of the 2 studies where antioxidants were delivered via enteral nutrition, antioxidant supplementation was associated with a significant reduction in duration of ventilation (WMD -2.59, 95% CI -4.15, -1.04, $p=0.001$, heterogeneity $I^2=3\%$; figure 7). There was a trend towards a difference between the subgroups ($p=0.10$).

Conclusions:

- 1) Antioxidant nutrients are associated with a trend towards a reduction in overall mortality in critically ill patients.
- 2) Antioxidant nutrients are associated with a trend towards a reduction in overall infectious complications in critically ill patients.
- 3) Antioxidant nutrients have no effect on ICU length of stay in critically ill patients.
- 4) Antioxidant nutrients have no effect on hospital length of stay in critically ill patients.
- 5) Antioxidant nutrients are associated with a trend towards a reduction in duration of ventilation in critically ill patients.

Level 1 study: if all of the following are fulfilled: concealed randomization, blinded outcome adjudication and an intention to treat analysis.

Level 2 study: if any one of the above characteristics are unfulfilled.

Table 1. Randomized Studies Evaluating Supplemental Combined Vitamins And Trace Elements in Critically Ill Patients

Study	Population	Methods Score	Intervention
Studies in which antioxidants were delivered via PN			
1) Kuklinski 1991	Patients with acute pancreatic necrosis N=17	C. Random: not sure ITT: no Blinding: no (4)	PN + selenium supplementation (500 µg /d) vs. PN without selenium supplementation
2) Young 1996	Severely head injured patients, ventilated N=68	C. Random: yes ITT: yes Blinding: double (7)	12 mg elemental zinc via PN, then progressing to oral zinc from 0- 15 days vs. 2.5 mg elemental zinc, then progressing to oral placebo
3) Zimmerman 1997	Patients with SIRS, APACHE > 15 and multiorgan failure score >6 N=40	C. Random: no ITT: yes Blinding: no (6)	1000 µg Na-Selenite as a bolus IV then 1000µg Na-Selenite/24 hrs as a continuous infusion over 28 days vs. standard
4) Berger 1998	Burns > 30 % TBSA N=20	C. Random: yes ITT: yes Blinding: double blind (12)	IV Copper (40.4 µmol), selenium (159 µg), zinc (406 µmol) + standard trace elements vs. standard trace elements (Copper 20 µmol, selenium 32 µg, zinc 100 µmol) from day 0- 8, all received early EN
5) Angstwurm 1999	Patients with systematic inflammatory response syndrome from 11 ICUs N=42	C. Random: not sure ITT: yes Blinding: no (10)	PN with high dose selenium (535 µg x 3 days, 285 µg x 3 days and 155 µg x 3 days and 35 µg thereafter) vs. low dose selenium (35 µg/day for duration of study)
6) Berger 2001	Trauma patients, surgical ICU N=32	C. Random: yes ITT: no Blinding: double blind (9)	IV Selenium supplementation (500 µg/day) vs. placebo (Selenium group randomized further to two groups: 500 µg Selenium alone vs. 500 µg Selenium + 150 mg α tocopherol + 13 mg zinc) given slowly for 1 st 5 days after injury (All groups received EN)
7) Lindner 2004	Patients with acute pancreatitis admitted to the ICU N=70	C. Random: not sure ITT: no Blinding: single (9)	IV sodium selenite dose of 2000 µg on day 1, 1000 µg on days 2-5, and 300 µg from day 6 until discharge vs placebo (isotonic 0.9% IV NaCl solution).

8) Angstwurm 2007	Multicentre mixed ICUs N=249	C.Random: not sure ITT: no Blinding: double (8)	1000µg Selenium IV within 1 hr followed by 1000µg Selenium for 14 days vs. NaCl (0.9%) (all patients received EN or PN)
9) Berger 2007	Burns > 20 % TBSA N=21	C.Random: not sure ITT: yes Blinding: no (8)	IV 100 ml of Copper (59 µmol) + Selenium (375 µgm + zinc (574 µmol) vs. NaCl (0.9%) from admission for 5-15 days. Both groups were on EN.
10) Forceville 2007	Septic shock patients from 7 ICUs N=60	C.Random: not sure ITT: no Blinding: double (8)	4000µg Selenium IV on day 1 followed by 1000µg Selenium for 9 days vs. NaCl (0.9%) (all patients received EN or PN)
11) Mishra 2007	Septic ICU patients N=40	C.Random: not sure ITT: yes Blinding: double (9)	474 µg Selenium IV x 3 days followed by 316 µg x 3 days, 158 µg x 3 days and 31.6 µg thereafter vs. 31.6 µg Selenium (all patients received EN or PN).
12) El-Attar 2009	COPD patients N=80	C.Random: yes ITT: yes Blinding: yes (12)	IV selenium as sodium selenite 100 µg/day, zinc 2 mg/day and manganese 0.4 mg/day vs. none. TE were administered during the period on mechanical ventilation
13) González 2009	Medical/surgical ICU pts N=68	C.Random: yes ITT: yes Blinding: double (7)	day 1 sodium selenite 1000µg , day 2 sodium selenite 500 µg and thereafter 200 µg during seven additional days vs selenite 100 µg/d
14) Andrews 2011	Mixed ICU N=502	C. Random: yes ITT: yes Blinding: double (13)	500µg selenium supplemented PN (12.5g nitrogen, 2000kcal) vs. standard PN (12.5g nitrogen, 2000kcal) initiated after ICU admission (actual median 2.6 days) for 7 days (actual duration, mean 4.1 days).
15) Manzanares 2011	Septic or trauma patients N=31	C. Random: not sure ITT: no (except mortality) Blinding: single (9)	IV Selenium supplementation loading dose 2000 µg (2 hours) on day 1 followed by 1600µg/day for 10 days vs. NaCl as placebo

16) Valenta 2011	Patients with sepsis or SIRS N=150	C. Random: not sure ITT: yes Blinding: no (8)	IV Selenium supplementation loading dose 1000 µg on day 1 followed by 500µg/day for 5-14 days + <75µg/day of Na-selenite added to PN. vs. NaCl + <75µg/day of Na-selenite added to PN.
17) Woth 2014	Mixed ICU, severe septic pts w multi-organ failure N=40	C. Random: not sure ITT: yes Blinding: no (6)	1000-µg/30 minutes loading dose of Na selenite and 1000-µg/die treatment for a maximum of 14 days vs control group (not described).
18) Bloos, In Submission	Multicentre Mixed ICU pts with severe sepsis or septic shock in last 24 hrs. N=1180	C. Random: yes ITT: yes Blinding: double (12)	IV loading dose of 1000 µg sodium selenite followed by continuous IV of 1000 µg sodium selenite daily until ICU discharge or for 21 days, whichever comes first vs placebo (0.9% sodium chloride).
Studies in which antioxidants were delivered via EN			
19) Maderazo 1991	Blunt Trauma N=46	C. Random: yes ITT: yes Blinding: double (7)	200 mg Ascorbic acid, then ↑ 500 mg + 50 mg α tocopherol in 100 ml of D5W vs. 100 ml of D5W (Experimental group divided into 2 groups, 200 mg ascorbic acid vs. 50 mg α tocopherol) .Given as 2 hr infusions from Day 0-7. (All groups received enteral nutrition or po intake)
20) Preiser 2000	Mixed ICU N=51	C. Random: not sure ITT: no Blinding: single (7)	Antioxidant rich formula via EN (133 µg /100 ml vit. A, 13 mg/100 ml Vit C & 4.9 mg/100 ml Vit E) vs. isonitrogenous, isocaloric standard formula (67 µg /100 ml vit. A, 5 mg/100 ml Vit C and 0.81 mg/100 ml Vit E) from Day 0- 7
21) Nathens 2002	General Surgical/Trauma ICU N=770	C. Random: not sure ITT: no Blinding: no (7)	α tocopherol 1000 IU q 8 h via naso or orogastric tube and ascorbic acid 1000 mg q 8 h via IV vs. standard care
22) Crimi 2004	Mixed ICU N=224	C. Random: not sure ITT: no Blinding: no (7)	Vit C (500 mg), Vit E (400 IU) within 72 hrs for 10 days vs. isotonic saline (all groups received EN)
23) Schneider 2011	ICU patients with sepsis or SIRS N=58	C. Random: not sure ITT: yes Blinding: single blind (8)	Fresenius Kabi Intestamin (300µg selenium, zinc 20mg, vitamin C 1500mg, Vitamin E 500mg) vs. Fresubin original plus 250mL water delivered via duodenal tube and initiated within first 48h of ICU admission. Both groups received Fresenius Kabi original fiber and supplemental PN if <60% adequacy

24) Nogueira 2013	ICU pts requiring EN (80% post-op, 20% medical) N=70	C.Random: not sure ITT: no Blinding: no (4)	'Hospital routine' EN + 10 000 IU retinol acetate, 400 mg vit E, 600 mg vit C vs 'hospital routine' EN. <i>Note: 'hospital routine' not defined in article.</i>
Studies in which antioxidants were delivered simultaneously via PN and EN			
25) Porter 1999	Surgical ICU Penetrating trauma patients with injury severity score ≥25 N=18	C. Random: yes ITT: yes Blinding: no (9)	50 µg selenium IV q 6 hrs + 400 IU Vit E, 100 mg Vit. C q 8 hrs and 8 g of N-acetylcysteine (NAC) q 6 hrs via nasogastric or oral route, from Day 0-7 vs. none
26 Berger 2008	Mixed ICU N=200	C.Random: not sure ITT: yes Blinding: no (10)	IV Selenium supplementation loading dose 540 µg/day + zinc (60 mg) + Vit C 2700 mg + Vit B 305 mg + Vit E enteral 600 mg + Vit E 12.8 mg IV for 2 days followed by half the dose of all vs. standard vitamins. (All groups received EN or PN)
27) Heyland 2013	Multicentre mixed ICUs N=1218	C.Random: yes ITT: yes Blinding: double (12)	500 µg selenium via PN + 300 µg selenium, 20 mg zinc, 10 mg beta carotene, 500 mg vitamin E, 1500 mg vitamin C via EN vs. placebo via PN and EN

D5W: dextrose 5% in water
TBSA: total body surface area

Table 1. Randomized Studies Evaluating Combined Vitamins And Trace Elements in Critically Ill Patients (continued)

Study	Mortality		Infections		LOS		Ventilator Days	
	Experimental	Control	Experimental	Control	Experimental	Control	Experimental	Control
Studies in which antioxidants were delivered via PN								
1) Kuklinski 1991	ICU 0/8 (0)	ICU 8/9 (89)	NR	NR	NR	NR	NR	NR
2) Young 1996	4/33 (12)	9/35 (26)	NR	NR	NR	NR	NR	NR
3) Zimmerman 1997	3/20 (15)	8/20 (40)	NR	NR	NR	NR	NR	NR

4) Berger 1998	1/10 (10)	0/10 (0)	1.9 ± 0.9 (1-4) per patient	3.1 ± 1.1 (2-5) per patient	ICU 30 ± 12 (10) Hospital 54 ± 27 (10)	ICU 39 ± 13 (10) Hospital 66 ± 31 (10)	9 ± 10 (10)	12 ± 9 (10)
5) Angstwurm 1999	Hospital 7/21 (33)	Hospital 11/21 (52)	NR	NR	NR	NR	9 (3-23)	10 (1-43)
6) Berger 2001	(a) Se alone 2/9 (22) (b) Se+AT+Zn 0/11 (0)	1/11 (9)	(a) Se alone 5/9 (56) (b) Se+AT+Zn 3/11 (27)	5/12 (42)	(a) Se alone ICU 8.0 ± 4.0 (9) Hospital 82 ± 78 (9) (b) Se+AT+Zn ICU 5.8 ± 4.4 (11) Hospital 60 ± 48 (11)	ICU 8.6 ± 8.1 (11) Hospital 64 ± 39 (11)	(a) Se alone 6.2 ± 3.5 (9) (b) Se+AT+Zn 4.1 ± 3.6 (11)	4.2 ± 5.2 (11)
7) Linder 2004	Not specified 5/32 (15.6)	Not specified 3/35 (8.6)	NA	NA	Hospital 24 (9-44)	Hospital 26 (11-46)	NA	NA
8) Angstwurm 2007	28-day 46/116 (40)	28-day 61/122 (50)	HAP 10/116 (9)	HAP 10/122 (8)	ICU 15.1 ± 10 (116)	ICU 12.7 ± 9 (122)	NR	NR
9) Berger 2007	1/11 (9)	1/10 (10)	2.1 ± 1.0 per pt	3.6 ± 1.3 per pt	ICU 35 ± 27 (11)	ICU 47 ± 37 (10)	7.6 ± 6 (11)	12.6 ± 6 (10)
10) Forceville 2007	28-day 14/31 (45) 6-month 18/31 (59) 1-year 66%	28-day 13/29 (45) 6-month 20/29 (68) 1-year 71%	Superinfection 1/31 (3)	Superinfection 2/29 (7)	ICU 21 (7-40) Hospital 25 (7-68)	ICU 18 (10-31) Hospital 33 (11-51)	19 (7-34)	14 (8-23)

11) Mishra 2007	ICU 8/18 (44) Hospital 11/18 (61) 28-day 8/18 (44)	ICU 11/22 (61) Hospital 15/22 (68) 28-day 11/22 (50)	1.5 ± 1.9 per patient	1.8 ± 1.6 per patient	ICU 21.3 ± 16.2 (18)	ICU 20.8 ± 21.8 (18)	NR	NR
12) El-Attar 2009	ICU 2/40 (5)	ICU 1/40 (3)	VAP 5/36 (14)	VAP 7/34 (21)	NR	NR	9.4 ± 7.3 (40)	17.8 ± 7.6 (40)
13) González 2009	Hospital 6/34 (18)	Hospital 8/34 (24)	NR	NR	Hospital 12(12-14)	Hospital 17(14-20)	9 (7-12)	13 (8-14)
14) Andrews 2011	ICU 84/251 (33) 6-month 107/251 (43)	ICU 84/251 (33) 6-month 114/251 (45)	Confirmed 104/251 (41)	Confirmed 121/251 (48)	ICU 13.2 (IQR 7.8, 23.7) Hospital 29.8 (IQR 14.7, 52.4)	ICU 15.1 (IQR 8.3, 28.4) Hospital 31.2 (IQR 15.1-57.8)	NR	NR
15) Manzanares 2011	ICU 3/15 (20) Hospital 5/15 (33)	ICU 5/16 (31) Hospital 7/16 (44)	VAP 3/15 (20)	VAP 7/16 (44)	ICU 14 ± 11 (15)	ICU 13 ± 6 (16)	10 ± 8 (15)	9 ± 4 (16)
16) Valenta 2011	28-day 19/75 (25)	28-day 24/75 (32)	NR	NR	NR	NR	NR	NR
17) Woth 2014	In 14 day study period 9/21 (43)	In 14 day study period 11/19 (58)	Gram negative 8/21 (38) Gram positive 3/21 (14) Fungal 1/21 (5)	Gram negative 3/19 (16) Gram positive 2/19 (11) Fungal 0/19 (0)	NR	NR	NR	NR
18) Bloos, In submission	Confidential data							

Studies in which antioxidants were delivered via EN								
19) Maderazo 1991	NR	NR	13/28 (46)	5/18 (28)	NR	NR	NR	NR
20) Preiser 2000	ICU 3/20 (15) Hospital 8/20 (40)	ICU 3/17 (18) Hospital 6/17 (35)	3/20 (15)	1/17 (6)	5 (3-26)	5 (3-18)	NR	NR
21) Nathens 2002	ICU 3/301 (1) Hospital 5/301(2) 28-day 4/301 (1)	ICU 9/294 (3) Hospital 9/294(3) 28-day 7/294 (2)	36/301 (12)	44/294 (15)	ICU 5.3 (mean) Hospital 14.6 (mean)	ICU 6.4 (mean) Hospital 15.1 (mean)	3.7 (mean)	4.6 (mean)
22) Crimi 2004	28-day 49/112 (44)	28-day 76/112 (68)	NR	NR	Hospital 26.5 (mean)	Hospital 27.5 (mean)	6.2 ± 2.3 (112)	8.9 ± 1.8 (112)
23) Schneider 2011	6/29 (21)	6/29 (21)	From day 8 13/26 (50)	From day 8 9/24 (38)	ICU 29.8 ± 26 (29) Hospital 44.4 ± 36.6 (29)	ICU 26.5 ± 19.6 (29) Hospital 47.2 ± 48.1 (29)	30.5 ± 19.2 (21)	27.2 ± 18.1 (19)
24) Nogueira	25% of total deaths Actual data not reported	75% of total deaths Actual data not reported	NR	NR	Hospital 30 ± 11	Hospital 27 ± 11	28% of vent needs Actual data not reported	72% of vent needs Actual data not reported
Studies in which antioxidants were delivered simultaneously via PN and EN								
25) Porter 1999	0/9	0/9	5/9 (56)	8/9 (89)	ICU 22 ± 25.2 (9) Hospital 31.3 ± 23.4 (9)	ICU 35.8 ± 21.9 (9) Hospital 49 ± 30 (9)	NR	NR
26) Berger 2008	ICU 8/102 (8) Hospital 14/102 (14) 3-month 14/602 (14)	ICU 5/98 (5) Hospital 9/98 (9) 3-month 11/98 (11)	36/102 (35)	34/98 (35)	ICU 5.8 ± 5.4 (102) Hospital 23 ± 20 (102)	ICU 5.4 ± 5.7 (98) Hospital 26 ± 20 (98)	Vent-free days 26.1 ± 5.7	Vent-free days 26.6 ± 5.2

<p>27) Heyland 2013</p>	<p>Hospital 216/617 (35) 14-day 154/617 (25) 28-day 190/617 (31) 3-month 239 (36) 6-month 250 (40)</p>	<p>Hospital 199/601 (33) 14-day 132/601 (22) 28-day 173/601 (29) 3-month 222 (36) 6-month 235(41)</p>	<p>All 168/617 (27) VAP 71/617 (12)</p>	<p>All 181/601 (30) VAP 95/601 (16)</p>	<p>ICU 14.2 ± 22.7 (617) Hospital 31.2 ± 50.2 (617)</p>	<p>ICU 13.8 ± 23.1 (601) Hospital 29.5 ± 44.8 (601)</p>	<p>10.9 ± 21.4 (617)</p>	<p>10.5 ± 19.7 (601)</p>
-------------------------	---	--	---	---	---	---	--------------------------	--------------------------

Figure 1. Overall Mortality (with sub-analyses according to routes of administration)




Figure 2: Mortality (with sub-analyses according to high (>10%) or low mortality in the control group)




Figure 3. Infections (with sub-analyses according to routes of administration)




Figure 4. Infections (with sub-analyses according to high (>10%) or low mortality in the control group)




Figure 5. ICU LOS




Figure 6. Hospital LOS




Figure 7. Duration of mechanical ventilation

